Cargando…

Which are the antibodies to watch in 2013?

The start of the new year signals that it is time for mAbs’ annual review of the therapeutic monoclonal antibodies (mAbs) in active Phase 2/3 or Phase 3 clinical studies. The entire clinical pipeline currently includes ~350 mAbs, but most of these are in early development. As of the beginning of 201...

Descripción completa

Detalles Bibliográficos
Autor principal: Reichert, Janice M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564874/
https://www.ncbi.nlm.nih.gov/pubmed/23254906
http://dx.doi.org/10.4161/mabs.22976

Ejemplares similares